Takeda Pharmaceutical (TKPHF) Cost of Revenue (2017 - 2026)

Takeda Pharmaceutical's Cost of Revenue history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 1.96% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $16.1 billion (up 3.25% YoY), while the FY2026 annual figure was $10.4 billion, up 0.64% from the prior year.
• Cost of Revenue was $2.6 billion for Q1 2026 at Takeda Pharmaceutical, down from $2.6 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $8.1 billion in Q3 2025 to a low of $2.2 billion in Q3 2022.
• Historically, Cost of Revenue has averaged $3.2 billion across 5 years, with a median of $2.5 billion in 2025.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue retreated 11.72% in 2022, then jumped 205.79% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $2.4 billion in 2022, then increased by 8.67% to $2.6 billion in 2023, then retreated by 2.39% to $2.5 billion in 2024, then climbed by 4.63% to $2.6 billion in 2025, then slipped by 1.99% to $2.6 billion in 2026.
• The last three Cost of Revenue figures came in at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $8.1 billion (Q3 2025), per Business Quant data.